title: In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
abstract: Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p<0.001) and doxorubicin (p=0.017), drugs administered during induction therapy. In patients with t(12;21) (n=20), in vitro sensitivity to doxorubicin was an independent factor for MRD <0.1% (p=0.031; R(2)=0.66). Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29.
authors.affiliation: Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. gudmar.lonnerholm@kbh.uu.se
authors.forename: Gudmar
authors.initials: G
authors.lastname: Lönnerholm
authors.forename: Ingrid
authors.initials: I
authors.lastname: Thörn
authors.forename: Christer
authors.initials: C
authors.lastname: Sundström
authors.forename: Britt-Marie
authors.initials: BM
authors.lastname: Frost
authors.forename: Jonas
authors.initials: J
authors.lastname: Abrahamsson
authors.forename: Mikael
authors.initials: M
authors.lastname: Behrendtz
authors.forename: Jesper
authors.initials: J
authors.lastname: Heldrup
authors.forename: Stefan
authors.initials: S
authors.lastname: Jacobsson
authors.forename: Aihong
authors.initials: A
authors.lastname: Li
authors.forename: Tor
authors.initials: T
authors.lastname: Olofsson
authors.forename: Anna
authors.initials: A
authors.lastname: Porwit
authors.forename: Stefan
authors.initials: S
authors.lastname: Söderhäll
authors.forename: Rolf
authors.initials: R
authors.lastname: Larsson
authors.forename: Erik
authors.initials: E
authors.lastname: Forestier
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D018365:Neoplasm, Residual / Q000175:diagnosis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D011239:Prednisolone / Q000008:administration & dosage
chemical_list: D004317:Doxorubicin; D011239:Prednisolone